可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Mettler-Toledo International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $30.9B | |
|---|---|---|
| Revenue (ttm) | 4.1B | |
| Net income (ttm) | 905.6M | |
| EPS (ttm) | $44.4 | |
| Shares out | 20M | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 28.5x | |
| Volume | 128,542 | |
| Beta | 1.19 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B | +2.0% |
| Gross profit | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B | +2.4% |
| Operating income | $994.7M | $1.13B | $1.15B | $1.13B | $1.12B | +3.0% |
| Net income | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M | +3.1% |
| EPS (diluted) | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 | +6.4% |
| EBITDA | $1.10B | $1.24B | $1.15B | $1.25B | $1.24B | +3.1% |
| R&D | $169.8M | $177.1M | $185.3M | $189.4M | $199.4M | +4.1% |
| SG&A | $944.0M | $938.5M | $904.1M | $936.3M | $998.3M | +1.4% |
Recent company headlines from major financial publishers.
Revenue compounds at 4.5%-5.1% annually, supported by steady 200 bps pricing realization and gradual recovery in Chinese operations, while Western European and US operations sustain mid-single digit cash generation,. Operating margins normalize around 28.1% to 28.7%, and free cash flow generation exceeding $840M supports ongoing annual share count reductions.
Chinese demand inflects positively on government stimulus transmission and replacement cycles, while biopharmaceutical laboratory capex accelerates as interest rates ease. Consolidated organic revenue growth accelerates to 6.5%-7.5% annually, operating margins expand toward 29.5% via operating leverage and SternDrive productivity, and sustained share buybacks drive compounded EPS growth above 12%.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.5% | $979 | $1,008 | $1,039 | $1,073 | $1,112 |
| 9.0% | $910 | $933 | $959 | $987 | $1,017 |
| 9.5% | $850 | $870 | $891 | $914 | $939 |
| 10.0% | $799 | $815 | $833 | $852 | $873 |
| 10.5% | $753 | $767 | $782 | $799 | $816 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |